Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models

Fig. 2

Chronic treatment with DA-9803 slows plaque deposition and results in mild clearance of amyloid plaques in APP/PS1 mice. a Protocol for chronic gavage treatment of DA-9803 (n = 6) or control compound (n = 6) in 6-month-old APP/PS1 mice. Methoxy-XO4 injected intraperitoneally (IP) before each imaging session. bd Two-photon images of an angiogram (b) and of methoxy-positive amyloid plaques taken at baseline (c) and after 8 weeks of treatment (d) of a mouse treated with control compound. eg Two-photon images of an angiogram (e) and of methoxy-positive amyloid plaques taken at baseline (f) and after 8 weeks of treatment (g) of a mouse treated with DA-9803. h, k Amyloid plaque number (h) and amyloid plaque burden (k) during the course of 8-week treatment across conditions. Amyloid plaque burden and plaque number values compared to baseline values via nonparametric Mann–Whitney test. i, l Amyloid plaque number (i) and amyloid plaque burden (l) after 8 weeks of treatment across conditions. j, m Change in amyloid plaque number (j) and burden (m) at the end of treatment compared to baseline. Scale bar, 100 μm. Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page